Drug intelligence / Profile preview

PT-80

Development stage: Unknown
Lead developer: ProteoTech
Modality: Small Molecules

Overview

PT-80 is a small molecule therapeutic developed by ProteoTech for the treatment of Alzheimer's disease. It is designed to target and inhibit the formation or promote the clearance of Alzheimer's-related amyloid proteins, specifically beta-amyloid. According to company pipeline data from 2014, PT-80 had completed animal studies and Phase 1 safety trials. ProteoTech, the developer, focused on misfolded protein diseases and amyloidosis, though the company's current operational status is unknown as its domain is no longer active.

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on PT-80.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PT-80.

Explore the full profile